Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 6Sarcoma 2Neoplasm Metastasis 2Nasopharyngeal Carcinoma 2Endometrial Neoplasms 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Ovarian Neoplasms 1Neoplasms 1Lung Neoplasms 1Gynecological Cancer 1Glioblastoma 1Craniopharyngioma 1Carcinoma, Hepatocellular 1Anlotinib 1Adenocarcinoma of Lung 1

Interventions

anlotinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Gynecological Cancer × anlotinib × Clear all
NCT04236362 2021-01-12

A Study of TQB2450 Combined With Anlotinib in Subjects With Gynecological Cancer

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 1/2 Unknown
90 enrolled

Gynecological Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡